Orthobiologics Market Size To Reach $9.3 Billion By 2030

Orthobiologics Market Growth & Trends

The global orthobiologics market size is expected to reach USD 9.3 billion by 2030, registering a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing cases of orthopedic surgeries across the globe is driving the demand for orthobiologics. A study presented at the Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) 2023, revealed that orthopedic surgeons would face a challenge in meeting the increasing demand for total joint arthroplasty (TJA). The study found that to keep up with the demand, surgeons will have to either double their TJA caseload or increase the number of surgeons by 10% every five years.

With an increasing focus on healthcare advancements and patient outcomes, governments worldwide are implementing policies and initiatives to foster the growth of orthobiologics. For instance, the American Academy of Orthopedic Surgeons (AAOS) is committed to improving musculoskeletal care in a transparent and scientific way. In October 2020, the AAOS launched the Biologics Dashboard on their website, which is designed to assist orthopedic surgeons in keeping track of the approval status of biologic-based interventions. This initiative is a part of the AAOS Biologics Initiative, which offers evidence-based guidance to the musculoskeletal health community. As part of this effort, the AAOS Board of Directors also revised two position statements related to biologics.

Increasing geriatric population across the globe is also anticipated to boost the demand for orthopedic surgeries. According to the India Ageing Report 2023, country’s elderly population is growing at a rapid pace, with a decadal growth rate of 41%. By 2050, over 20% of India's population will be elderly citizens.As people age, they are more likely to experience issues with their muscles and bones, such as osteoporosis, osteoarthritis, and fractures. This results in a greater need for orthobiologics solutions.

Moreover, increasing cases of road accidents is anticipated to supplement the market growth. According to the National Highway Traffic Safety Administration report, there were an estimated 19,515 deaths in motor vehicle accidents during the first half of 2023. This represents a decrease of about 3.3% compared to the same period in the previous year, which had 20,190 fatalities. The report also shows that fatalities decreased during both the first and second quarters of 2023. Thus, the increasing number of injured populations is expected to increase the demand for orthobiologics.

The major players operating in the market are adopting strategies such as collaborations, supply agreements, and partnerships with a major focus on enhancing the product formation and reach. For instance, inSeptember 2023, HippoFi Inc. partnered with Zimmer Biomet Holdings Inc. to bring forth a synthetic biomaterial for bone growth. The biomaterial will be launched under HippoFi's biologic subsidiary, PUR Biologics in 2024.

 Request a free sample copy or view report summary: Orthobiologics Market Report

Orthobiologics Market Report Highlights

• Based on product, the viscosupplementation segment held the largest revenue share in the market in 2023 owing to the increasing prevalence of lifestyle-related conditions and advances in hyaluronic acid therapy development

• Based on application, the spinal fusion segment held the largest revenue share in the market in 2023 owing to the rising incidence of degenerative disc disease

• Based on end-use, the hospitals segment accounted for the largest revenue share due to the growing patient population undergoing surgical procedures

• North America dominated the market due to the presence of several market players and a well-established regulatory framework

Orthobiologics Market Segmentation

Grand View Research has segmented the global orthobiologics market based on product, application, end-use, and region:

Orthobiologics Product Outlook (Revenue, USD Million, 2018 - 2030)

• Demineralized Bone Matrix (DBM)

• Allograft

• Bone Morphogenetic Protein (BMP)

• Viscosupplementation

• Synthetic Bone Substitutes

• Stem Cell Therapy

Orthobiologics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Spinal Fusion

• Trauma Repair

• Reconstructive Surgery

• Stem Cell Therapy

Orthobiologics End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Outpatient Facilities

Orthobiologics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • Spain

  • Italy

  • France

  • Denmark

  • Norway

  • Sweden

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Orthobiologics Market

• Medtronic Plc

• DePuy Synthes

• Zimmer Biomet

• Stryker Corporation

• Bioventus LLC

• Anika Therapeutics, Inc.

• Orthofix, Inc.

• Globus Medical

• Arthrex, Inc.

• Bone Biologics Corp.